Cargando…

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placeb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fautrel, Bruno, Kirkham, Bruce, Pope, Janet E., Takeuchi, Tsutomu, Gaich, Carol, Quebe, Amanda, Zhu, Baojin, de la Torre, Inmaculada, De Leonardis, Francesco, Taylor, Peter C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780319/ https://www.ncbi.nlm.nih.gov/pubmed/31492040 http://dx.doi.org/10.3390/jcm8091394

Ejemplares similares

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
por: Michaud, Kaleb, et al.
Publicado: (2019)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
por: Keystone, Edward C, et al.
Publicado: (2017)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
por: Alten, Rieke, et al.
Publicado: (2022)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
por: Fautrel, B, et al.
Publicado: (2020)

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
por: Smolen, Josef S, et al.
Publicado: (2017)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
por: Yang, Yue, et al.
Publicado: (2020)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN
por: López-Romero, Pedro, et al.
Publicado: (2020)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials
por: Fautrel, Bruno, et al.
Publicado: (2023)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
por: Alten, Rieke, et al.
Publicado: (2023)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
por: Fakhouri, Walid, et al.
Publicado: (2020)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
por: Bergman, Martin, et al.
Publicado: (2023)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
por: Fautrel, Bruno, et al.
Publicado: (2018)

Mortality in Rheumatoid Arthritis (RA): factors associated with recording RA on death certificates
por: Molina, Emily, et al.
Publicado: (2015)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
por: Combe, Bernard, et al.
Publicado: (2019)

Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target
por: Taylor, Peter C., et al.
Publicado: (2021)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA
por: Amrhein, Jan, et al.
Publicado: (2020)

Massive nodulous lesions on hands and feet in a RA patient and improvement under baricitinib treatment
por: Valor-Méndez, Larissa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qf5u5m25uc76r907qkku5c4o8q